bluebird bio, Inc. (NASDAQ:BLUE) Receives $49.14 Average PT from Analysts

bluebird bio, Inc. (NASDAQ:BLUE) has earned a consensus recommendation of “Hold” from the ten brokerages that are presently covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating on the company. The average 12 month price target among brokerages that have issued ratings on the stock in the last year is $49.14.

BLUE has been the subject of a number of recent analyst reports. Cantor Fitzgerald reaffirmed a “neutral” rating on shares of bluebird bio in a report on Monday, September 16th. StockNews.com started coverage on shares of bluebird bio in a report on Friday. They set a “sell” rating on the stock. Royal Bank of Canada restated a “sector perform” rating and issued a $80.00 target price on shares of bluebird bio in a report on Friday, November 15th. JPMorgan Chase & Co. downgraded shares of bluebird bio from a “neutral” rating to an “underweight” rating in a research report on Friday, November 15th. Finally, Wells Fargo & Company reduced their price target on shares of bluebird bio from $60.00 to $40.00 and set an “equal weight” rating for the company in a research report on Wednesday, September 25th.

Institutional Investors Weigh In On bluebird bio

Several hedge funds have recently made changes to their positions in BLUE. AQR Capital Management LLC raised its stake in bluebird bio by 315.3% during the 2nd quarter. AQR Capital Management LLC now owns 1,334,519 shares of the biotechnology company’s stock valued at $1,223,000 after acquiring an additional 1,013,144 shares during the last quarter. BNP Paribas Financial Markets raised its position in bluebird bio by 2,270.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock worth $193,000 after buying an additional 355,562 shares during the last quarter. FMR LLC raised its position in bluebird bio by 8.1% during the 3rd quarter. FMR LLC now owns 2,481,965 shares of the biotechnology company’s stock worth $1,289,000 after buying an additional 186,903 shares during the last quarter. Barclays PLC lifted its stake in shares of bluebird bio by 273.7% in the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock worth $130,000 after acquiring an additional 184,605 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in shares of bluebird bio by 3.7% in the third quarter. Geode Capital Management LLC now owns 4,683,042 shares of the biotechnology company’s stock valued at $2,433,000 after acquiring an additional 166,771 shares in the last quarter. Institutional investors and hedge funds own 87.43% of the company’s stock.

bluebird bio Stock Down 7.9 %

Shares of NASDAQ:BLUE opened at $8.50 on Wednesday. bluebird bio has a fifty-two week low of $5.80 and a fifty-two week high of $38.40. The firm’s 50 day moving average price is $8.53 and its 200 day moving average price is $13.68. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The stock has a market cap of $82.64 million, a price-to-earnings ratio of -4.55 and a beta of 0.72.

bluebird bio (NASDAQ:BLUE) last announced its quarterly earnings data on Friday, September 27th. The biotechnology company reported ($8.40) earnings per share for the quarter, missing analysts’ consensus estimates of ($8.00) by ($0.40). The firm had revenue of $16.10 million during the quarter, compared to analyst estimates of $16.09 million. bluebird bio had a negative net margin of 565.74% and a negative return on equity of 322.46%. As a group, equities research analysts predict that bluebird bio will post -1.35 earnings per share for the current fiscal year.

About bluebird bio

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.